These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 24391105)
1. How to spot heritable breast cancer: a primary care physician's guide. Smith M; Mester J; Eng C Cleve Clin J Med; 2014 Jan; 81(1):31-40. PubMed ID: 24391105 [TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. American Society of Clinical Oncology J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171 [TBL] [Abstract][Full Text] [Related]
3. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information. DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341 [TBL] [Abstract][Full Text] [Related]
4. Genetic counseling for breast cancer risk: how did we get here and where are we going? Lang KA Expert Rev Mol Diagn; 2013 Jul; 13(6):541-51. PubMed ID: 23895125 [TBL] [Abstract][Full Text] [Related]
5. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers? Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258 [TBL] [Abstract][Full Text] [Related]
6. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732 [TBL] [Abstract][Full Text] [Related]
7. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. Shulman LP Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261 [TBL] [Abstract][Full Text] [Related]
8. Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. Arnold AG; Otegbeye E; Fleischut MH; Glogowski EA; Siegel B; Boyar SR; Salo-Mullen E; Amoroso K; Sheehan M; Berliner JL; Stadler ZK; Kauff ND; Offit K; Robson ME; Zhang L Breast Cancer Res Treat; 2014 Jun; 145(3):625-34. PubMed ID: 24825132 [TBL] [Abstract][Full Text] [Related]
9. Mother still knows best: cancer-related gene mutations, familial privacy, and a physician's duty to warn. Brownrigg A Fordham Urban Law J; 1999 Jan; 26(2):247-79. PubMed ID: 16437785 [No Abstract] [Full Text] [Related]
10. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center. Shannon KM; Lubratovich ML; Finkelstein DM; Smith BL; Powell SN; Seiden MV Cancer; 2002 Jan; 94(2):305-13. PubMed ID: 11900216 [TBL] [Abstract][Full Text] [Related]
11. Hereditary breast cancer. Psychosocial issues and family physicians' role. Carroll JC; Heisey RE; Warner E; Goel V; McCready DR Can Fam Physician; 1999 Jan; 45():126-32. PubMed ID: 10889865 [TBL] [Abstract][Full Text] [Related]
12. Direct-to-patient BRCA1 testing: the Twoj Styl experience. Gronwald J; Huzarski T; Byrski T; Debniak T; Metcalfe K; Narod SA; LubiĆski J Breast Cancer Res Treat; 2006 Dec; 100(3):239-45. PubMed ID: 16807675 [TBL] [Abstract][Full Text] [Related]
13. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502 [TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
15. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future. Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443 [TBL] [Abstract][Full Text] [Related]
16. Genetic counseling, testing, and screening for breast and ovarian cancer: practical and social considerations. Khabele D; Runowicz CD Curr Womens Health Rep; 2002 Jun; 2(3):163-9. PubMed ID: 12099190 [TBL] [Abstract][Full Text] [Related]
17. [Genetic testing in patients at risk for carcinoma of the breast]. Kiechle M Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060 [No Abstract] [Full Text] [Related]
18. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627 [TBL] [Abstract][Full Text] [Related]
19. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation. Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684 [TBL] [Abstract][Full Text] [Related]